Navidea Biopharmaceuticals, Inc. (nyse mkt:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced results from a post-hoc analysis of patient data from the Company’s Phase 3 clinical trial (NEO3-06) of Lymphoseek in head and neck cancer. The ability of Lymphoseek to localize in sentinel lymph nodes is based on its ability to target specific CD206 mannose receptor sites in macrophages, a type of immune cell which resides in high concentration in lymph nodes. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) weekly performance is 20.00%. On last trading day company shares ended up $1.92. Analysts mean target price for the company is $2.81. Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB) distance from 50-day simple moving average is 18.10%.
BSD Medical Corporation (NASDAQ: BSDM) announced initiation of a clinical study by the University of Utah School of Medicine using BSD’s MicroThermX® Microwave Ablation System (MicroThermX) to treat liver tumors. The study is a prospective, non-randomized, single arm trial that involves 20 patients. The study objective is to clinically evaluate the size of the ablation zones produced in liver tissue by BSD’s patented Synchronous Wave Alignment™ technology developed for MicroThermX. BSD Medical Corporation (NASDAQ:BSDM) shares ended the day on $1.07. BSDM Gross Margin is 44.20% and its return on assets is -52.60%. BSD Medical Corporation (NASDAQ:BSDM) quarterly performance is -13.71%.
Sunshine Heart Inc (NASDAQ:SSH) announced that Chief Financial Officer, Jeff Mathiesen, is scheduled to present at the 2014 Wells Fargo Healthcare Conference at the InterContinental Hotel in Boston, MA on June 17th at 4:05 PM EST. Sunshine Heart Inc (NASDAQ:SSH) shares moved up 6.75% in last trading session and was closed at $5.69, while trading in range of $5.33-$5.86. Sunshine Heart Inc (NASDAQ:SSH) year to date performance is -40.58%.
Arrhythmia Research Technology, Inc. (NYSEMKT:HRT) ended the last trading day at $6.65. Company weekly volatility is calculated as 4.66% and price to cash ratio as 25.84. Arrhythmia Research Technology, Inc. (NYSEMKT:HRT) showed a positive weekly performance of 7.95%.
May 19, 2014 Vision-Sciences, Inc. (Nasdaq:VSCI), a leading provider of unique flexible endoscopic products utilizing its proprietary sterile disposable EndoSheath technology, announced the launch of its next generation video bronchoscope and EndoSheath technology. The new BRS-5100 video bronchoscope was unveiled at the annual ATS (American Thoracic Society) Meeting in San Diego, California on May 18 – 20, 2014. Vision-Sciences, Inc. (NASDAQ:VSCI) net profit margin is -45.40% and weekly performance is -0.85%. On last trading day company shares ended up $1.18. Analysts mean target price for the company is $3.00. Vision-Sciences, Inc. (NASDAQ:VSCI) distance from 50-day simple moving average is 3.96%.